New York State Teachers Retirement System Raises Stake in Supernus Pharmaceuticals Inc (SUPN)

New York State Teachers Retirement System increased its stake in Supernus Pharmaceuticals Inc (NASDAQ:SUPN) by 0.5% during the fourth quarter, Holdings Channel reports. The firm owned 77,035 shares of the specialty pharmaceutical company’s stock after buying an additional 400 shares during the period. New York State Teachers Retirement System’s holdings in Supernus Pharmaceuticals were worth $1,945,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Pacad Investment Ltd. bought a new position in Supernus Pharmaceuticals during the fourth quarter valued at $124,000. Stevens Capital Management LP bought a new position in Supernus Pharmaceuticals during the third quarter valued at $201,000. Campbell & CO Investment Adviser LLC bought a new position in Supernus Pharmaceuticals during the third quarter valued at $210,000. Osborn Rohs Williams & Donohoe Ltd bought a new position in Supernus Pharmaceuticals during the third quarter valued at $223,000. Finally, First Citizens Bank & Trust Co. bought a new position in Supernus Pharmaceuticals during the third quarter valued at $241,000. Hedge funds and other institutional investors own 94.94% of the company’s stock.

Institutional Ownership by Quarter for Supernus Pharmaceuticals (NASDAQ:SUPN)

Supernus Pharmaceuticals Inc (NASDAQ:SUPN) opened at 29.90 on Tuesday. The company’s 50 day moving average is $26.57 and its 200 day moving average is $24.05. The firm has a market cap of $1.49 billion, a P/E ratio of 16.99 and a beta of 1.89. Supernus Pharmaceuticals Inc has a 52-week low of $13.43 and a 52-week high of $30.37.

Your IP Address:

SUPN has been the subject of several research analyst reports. Jefferies Group LLC upped their price target on shares of Supernus Pharmaceuticals from $33.00 to $35.00 and gave the stock a “buy” rating in a research report on Wednesday, March 8th. Cantor Fitzgerald restated a “buy” rating and set a $32.00 price target on shares of Supernus Pharmaceuticals in a research report on Thursday, January 12th. Finally, Zacks Investment Research upgraded shares of Supernus Pharmaceuticals from a “hold” rating to a “buy” rating and set a $24.00 price target for the company in a research report on Tuesday, November 29th. Three equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $27.40.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company offers products for the treatment of epilepsy, which include extended-release oxcarbazepine (Oxtellar XR) and extended-release topiramate (Trokendi XR).

5 Day Chart for NASDAQ:SUPN

Want to see what other hedge funds are holding SUPN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Supernus Pharmaceuticals Inc (NASDAQ:SUPN).

Receive News & Ratings for Supernus Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply

 
© 2006-2017 Mideast Time.